Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Nurix Therapeutics (NASDAQ:NRIX) and maintained a $31 price target on the stock.

April 09, 2024 | 10:23 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum reiterates a Buy rating on Nurix Therapeutics and maintains a $31 price target.
The reiteration of a Buy rating and maintenance of a $31 price target by a reputable analyst like Gil Blum from Needham is likely to instill confidence among investors and could lead to a positive short-term impact on Nurix Therapeutics' stock price. Analyst ratings, especially from well-regarded financial institutions, can significantly influence investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100